Breast Cancer

Abraxis BioScience Reports 83% Revenue Growth to a Record $334 Million for 2007

Published in Lab Law Weekly, April 18th, 2008

Abraxis BioScience, Inc. (NASDAQ: ABII), a fully integrated biotechnology company, reported financial results for the fourth quarter and full year ended December 31, 2007.

Full-year 2007 net revenue increased 83.1 percent to $333.7 million, compared with $182.3 million in 2006. Revenue from sales of ABRAXANE(R) (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) grew 85.6 percent to $324.7 million in 2007 versus $174.9 million in 2006. ABRAXANE revenue included deferred recognized revenue of $36.4 million in 2007 and $18.2 million in 2006 as part of the June 2006 co-promotion agreement with AstraZeneca.

ABRAXANE continues...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Lab Law Weekly

Source: Lab Law Weekly (2008-04-18)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry